<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; threat</title>
	<atom:link href="http://www.tapanray.in/tag/threat/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>MAGA vs. Viksit Bharat: Trump&#8217;s Tariffs And India&#8217;s Pharma Dreams</title>
		<link>http://www.tapanray.in/maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams</link>
		<comments>http://www.tapanray.in/maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams/#comments</comments>
		<pubDate>Tue, 15 Apr 2025 08:32:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[dreams]]></category>
		<category><![CDATA[First]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MAGA]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reciprocal]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tariff]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[Vikshit]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10888</guid>
		<description><![CDATA[A high-stakes clash poses a potential threat to PM Modi&#8217;s &#8216;Viksit Bharat&#8217; Vision, exposing India&#8217;s pharmaceutical vulnerability and forcing a strategic reckoning. The resurgence of Donald Trump&#8217;s &#8220;America First&#8221; MAGA (Make America Great Again) agenda casts a long, ominous shadow &#8230; <a href="http://www.tapanray.in/maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/maga-vs-viksit-bharat-trumps-tariffs-and-indias-pharma-dreams/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>China Coronavirus And API Sourcing &#8211; A Threat… Or An Opportunity For India?</title>
		<link>http://www.tapanray.in/china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india</link>
		<comments>http://www.tapanray.in/china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india/#comments</comments>
		<pubDate>Mon, 03 Feb 2020 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2019-nCoV]]></category>
		<category><![CDATA[Active]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[green]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[Kerala]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repurposing]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[shoots]]></category>
		<category><![CDATA[sourcing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9858</guid>
		<description><![CDATA[‘2015 – Year of Active Pharmaceutical Ingredients’ (API), announced the Government of India by a Press Release on February 25, 2015. This came after ascertaining that over-dependence on imports of bulk drugs or API, especially from China, is detrimental to India’s health &#8230; <a href="http://www.tapanray.in/china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/china-coronavirus-and-api-sourcing-a-threat-or-an-opportunity-for-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Any Threat To Current Commercial Model Of ‘Gene Therapy’?</title>
		<link>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=any-threat-to-current-commercial-model-of-gene-therapy</link>
		<comments>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/#comments</comments>
		<pubDate>Mon, 30 Dec 2019 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CAR-T]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[current]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[disorders]]></category>
		<category><![CDATA[dynamics]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[genetic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[pipeline]]></category>
		<category><![CDATA[pricey]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[threat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9833</guid>
		<description><![CDATA[Wish All My Readers A Very Happy, Healthy, Peaceful and Prosperous 2020 &#160; One of the most complex areas in disease management, is the ailments related to genetic disorders. As these were incurable, over the last four decades, medical researchers &#8230; <a href="http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Link To Ponder: Pharma Digitalization – Cyber Threats &#8211; Cyber Immunity</title>
		<link>http://www.tapanray.in/a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity</link>
		<comments>http://www.tapanray.in/a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity/#comments</comments>
		<pubDate>Mon, 04 Nov 2019 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[attacks]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[criminals]]></category>
		<category><![CDATA[cyber]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[immunity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[ponder]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9776</guid>
		<description><![CDATA[Digitalization in the pharmaceutical industry – slowly but steadily, across its various domains, from drug discovery, clinical development, supply chain, sales and marketing to engage with various stakeholders, is a reality today. Consequently, the concept of data as a business &#8230; <a href="http://www.tapanray.in/a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Opioid Crisis: A Looming Threat To India?</title>
		<link>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=opioid-crisis-a-looming-threat-to-india</link>
		<comments>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/#comments</comments>
		<pubDate>Mon, 16 Sep 2019 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Atypical]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[flip side]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[looming]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[narcotics]]></category>
		<category><![CDATA[Nexus]]></category>
		<category><![CDATA[Opioid]]></category>
		<category><![CDATA[pain]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[tryst]]></category>
		<category><![CDATA[United States]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9712</guid>
		<description><![CDATA[A serious, but a typical health crisis that has shaken America, is now, apparently, in search of its prey in India – a soft target to ignite a raging fire of misuse or abuse of prescription drugs of addictive in &#8230; <a href="http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Exigency of Cybersecurity in Digitalized Pharma</title>
		<link>http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=exigency-of-cybersecurity-in-digitalized-pharma</link>
		<comments>http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/#comments</comments>
		<pubDate>Mon, 08 Oct 2018 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[attack]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[cyber]]></category>
		<category><![CDATA[cybersecurity]]></category>
		<category><![CDATA[digitalized]]></category>
		<category><![CDATA[digitized]]></category>
		<category><![CDATA[employee]]></category>
		<category><![CDATA[espionage]]></category>
		<category><![CDATA[exigency]]></category>
		<category><![CDATA[experienced]]></category>
		<category><![CDATA[hack]]></category>
		<category><![CDATA[hacking]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9204</guid>
		<description><![CDATA[Digitalization – as it unfolds and imbibed by most drug companies, is presumed to herald a whole new ballgame in the Indian pharma business. Equally significant is the quantum benefit that the process will deliver to pharma stakeholders – right &#8230; <a href="http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Threats to Indian Generics: Failing in US Inspections is Just Half The Story</title>
		<link>http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story</link>
		<comments>http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/#comments</comments>
		<pubDate>Wed, 26 Feb 2014 09:44:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[Cleveland]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[failing]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[half]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[inspection]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Margaret]]></category>
		<category><![CDATA[Ohio]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[Toansa]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Wellbutrin XL]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5027</guid>
		<description><![CDATA[At a recent event of the American Enterprise Institute, Dr. Harry Lever, a senior cardiologist at the Cleveland Clinic in Ohio, reportedly expressed his concern based on his personal experience regarding inconsistent quality among Indian generics. As a result, he requires switching patients &#8230; <a href="http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vaccines Development: Is it Just a Business Based on Fear?</title>
		<link>http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=vaccines-development-is-it-just-a-business-based-on-fear</link>
		<comments>http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/#comments</comments>
		<pubDate>Mon, 26 Aug 2013 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[Buchwald]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[diphtheria]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[enough]]></category>
		<category><![CDATA[Expenses]]></category>
		<category><![CDATA[fear]]></category>
		<category><![CDATA[First]]></category>
		<category><![CDATA[Gates]]></category>
		<category><![CDATA[GAVI]]></category>
		<category><![CDATA[Gerhard]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[JV]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[MSD]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Partnership]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pox]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TB]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[Tuberculosis]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3486</guid>
		<description><![CDATA[‘Vaccination – A Business based on fear’, is the title of a book written by Dr. Gerhard Buchwald M.D, a German medical doctor and a vaccination critic. This book talks about: “The damage and the deaths caused by vaccination are written &#8230; <a href="http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India needs ‘Orphan Drugs Act (ODA)’ to counter growing threat of dreaded rare diseases and simultaneously boost global growth potential of the Indian Pharmaceutical Industry</title>
		<link>http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry</link>
		<comments>http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/#comments</comments>
		<pubDate>Mon, 01 Nov 2010 00:30:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[boost]]></category>
		<category><![CDATA[counter]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[dreaded]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[ODA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[simultaneous]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=354</guid>
		<description><![CDATA[An orphan disease is a rare and uncommon disease and an ‘Orphan Drug’ is a pharmaceutical substance that has been developed to treat an orphan disease. The US FDA defines a rare disease, with a prevalence of 1 in 5,000 &#8230; <a href="http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Recent appetite of Global Pharmaceutical Majors for Generic Pharmaceutical Business: can it pose a threat to pure generic players?</title>
		<link>http://www.tapanray.in/recent-appetite-of-global-pharmaceutical-majors-for-generic-pharmaceutical-business-can-it-pose-a-threat-to-pure-generic-players/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=recent-appetite-of-global-pharmaceutical-majors-for-generic-pharmaceutical-business-can-it-pose-a-threat-to-pure-generic-players</link>
		<comments>http://www.tapanray.in/recent-appetite-of-global-pharmaceutical-majors-for-generic-pharmaceutical-business-can-it-pose-a-threat-to-pure-generic-players/#comments</comments>
		<pubDate>Sun, 12 Apr 2009 04:30:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[appetite]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[can]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[majors]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[pose]]></category>
		<category><![CDATA[pure]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Recent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=918</guid>
		<description><![CDATA[Last year Lehman Brothers estimated that by 2012 over 25% of the global pharmaceutical market will face competition from generics. Higher demand of generics is mainly due to the following reasons:1. Increased number of patented drugs is going off-patent.2. Cost &#8230; <a href="http://www.tapanray.in/recent-appetite-of-global-pharmaceutical-majors-for-generic-pharmaceutical-business-can-it-pose-a-threat-to-pure-generic-players/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/recent-appetite-of-global-pharmaceutical-majors-for-generic-pharmaceutical-business-can-it-pose-a-threat-to-pure-generic-players/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
